Endocrinology

Predicting the outcome for newborns with congenital hyperinsulinism

Babies born with congenital hyperinsulinism (CHI) are at risk of suffering from permanent brain damage and life-long disability.

newborn baby feet
Source: Unsplash/Ignacio Campo

Yet some will go on to suffer more severely than others as a result of their disease profile, report the researchers in an article published in Frontiers in Endocrinology. The research team have found that it is possible to predict when and how the disease may affect the child in the long-term. “One of the problems facing clinicians is that it is really difficult to predict which babies will have problems after surgical treatment. Our new data give some important clues that will help clinicians to know how much extra care each baby is likely to need”, explains Dr Karen Cosgrove, a member of the research team from The University of Manchester. Although generally rare, affecting just 1 in 50,000 children in the UK, CHI can be as common as cystic fibrosis (1 in 2,500) in children of European Jewish descent or when born into communities where cousins marry.

Although the impact of these findings is limited to centres with surgical resources, for those centres the data is immediately applicable and translatable clinically

Mark Dunne

Up until now, scientists have understood that there are two main subtypes of the disease - known as diffuse and focal. Diffuse CHI affects the entire pancreas, whilst focal CHI affects just one area of the organ, forming a focal lesion. The team from Manchester now understand that focal CHI can be further categorised into two types- spreading focal lesions and isolated focal lesions. Spreading focal lesions are generally larger and spread outwards into areas of healthy cells. Isolated focal lesions, on the other hand, have a capsule around them which keeps the diseased cells separate from healthy cells.

The research team investigated the cases of 25 infants with focal CHI to see how the two types of lesions influenced their long-term outcomes. They found that babies with spreading focal lesions suffered more severely from the disease and were diagnosed earlier. These infants were more likely to suffer brain damage which permanently affected their development, learning and behaviour. In contrast, in infants with isolated lesions, the disease was diagnosed later and surgery to remove the lesion was less complicated.

These new data help to explain why new-born babies diagnosed with the same disease may go on to have very different outcomes and could influence the way clinicians choose to manage each new case of CHI. “Although the impact of these findings is limited to centres with surgical resources, for those centres the data is immediately applicable and translatable clinically” explains Professor Mark Dunne from The University of Manchester and lead author on the study.


Source: University of Manchester

02.04.2019

More on the subject:
Read all latest stories

Related articles

Photo

Meta-analysis

Benefit and risk: drug-coated balloon angioplasty

Scientists of Jena University Hospital, Germany, conducted a meta-analysis to evaluate benefit and risk of paclitaxel-coated balloon angioplasty compared to conventional balloon angioplasty as…

Photo

Major global study reveals

Colorectal, pancreatic cancer rates up 10% in last 30 years

The results of a major study across 195 countries, presented at UEG Week Barcelona 2019, indicate that global death rates for pancreatic cancer and incidence rates for colorectal cancer both…

Photo

Rehabilitation

Hope for patients in vegetative and minimally conscious states

Non-invasive brain stimulation is to be trialed for the first time alongside advanced brain imaging techniques in patients who are minimally conscious or in a vegetative state. The study builds on…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH